Find Liafensine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Bms-820836, Liafensine [usan], 1198790-53-2, R34id086z6, Liafensine (usan), Liafensine [usan:inn]
Molecular Formula
C24H22N4
Molecular Weight
366.5  g/mol
InChI Key
VCIBGDSRPUOBOG-QFIPXVFZSA-N
FDA UNII
R34ID086Z6

Liafensine
Liafensine is under investigation in clinical trial NCT00892840 (Multiple-Ascending Dose Study).
1 2D Structure

Liafensine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
6-[(4S)-2-methyl-4-naphthalen-2-yl-3,4-dihydro-1H-isoquinolin-7-yl]pyridazin-3-amine
2.1.2 InChI
InChI=1S/C24H22N4/c1-28-14-20-13-19(23-10-11-24(25)27-26-23)8-9-21(20)22(15-28)18-7-6-16-4-2-3-5-17(16)12-18/h2-13,22H,14-15H2,1H3,(H2,25,27)/t22-/m0/s1
2.1.3 InChI Key
VCIBGDSRPUOBOG-QFIPXVFZSA-N
2.1.4 Canonical SMILES
CN1CC(C2=C(C1)C=C(C=C2)C3=NN=C(C=C3)N)C4=CC5=CC=CC=C5C=C4
2.1.5 Isomeric SMILES
CN1C[C@H](C2=C(C1)C=C(C=C2)C3=NN=C(C=C3)N)C4=CC5=CC=CC=C5C=C4
2.2 Other Identifiers
2.2.1 UNII
R34ID086Z6
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 6-(2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine

2. Bms-820836

2.3.2 Depositor-Supplied Synonyms

1. Bms-820836

2. Liafensine [usan]

3. 1198790-53-2

4. R34id086z6

5. Liafensine (usan)

6. Liafensine [usan:inn]

7. Unii-r34id086z6

8. Bms 820836

9. Liafensine [inn]

10. Liafensine [who-dd]

11. Schembl1120067

12. Chembl2364614

13. Dtxsid60152610

14. Chebi:177531

15. Bdbm50459930

16. Db14878

17. D10443

18. Q18353685

19. (5)-6-(2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine

20. (s)-6-(2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine

21. 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine

22. 6-[(4s)-2-methyl-4-naphthalen-2-yl-3,4-dihydro-1h-isoquinolin-7-yl]pyridazin-3-amine

23. 3-pyridazinamine, 6-((4s)-1,2,3,4-tetrahydro-2-methyl-4-(2-naphthalenyl)-7-isoquinolinyl)-

24. 6-((4s)-2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine

2.4 Create Date
2012-08-19
3 Chemical and Physical Properties
Molecular Weight 366.5 g/mol
Molecular Formula C24H22N4
XLogP33.7
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count2
Exact Mass366.18444672 g/mol
Monoisotopic Mass366.18444672 g/mol
Topological Polar Surface Area55 Ų
Heavy Atom Count28
Formal Charge0
Complexity525
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty